Summary
Pfizer Inc. filed a Form 8-K on April 27, 2007, primarily to furnish XBRL-formatted financial data from its previously filed 2006 Annual Report (10-K). This filing includes the Consolidated Statements of Income, Balance Sheets, Cash Flows, and Shareholders' Equity for the years 2004 through 2006. It is crucial for investors to note that the XBRL-formatted data provided in this 8-K is considered unaudited for the purpose of this filing and is part of a voluntary SEC pilot program. Investors should continue to rely on the officially filed 10-K for decision-making, as this XBRL data is not deemed 'filed' under Section 18 of the Exchange Act and does not carry the same liability. The core financial information remains consistent with the initial 10-K filing.
Key Highlights
- 1Filing provides XBRL-formatted financial statements from Pfizer's 2006 10-K.
- 2Includes Consolidated Statements of Income, Balance Sheets, Cash Flows, and Shareholders' Equity for 2004-2006.
- 3XBRL data is part of a voluntary SEC pilot program to test the technology.
- 4Crucially, the XBRL data is considered unaudited for this 8-K filing and should not be the primary source for investment decisions.
- 5Investors are advised to rely on the official 10-K filing dated March 1, 2007.
- 6Information furnished in this 8-K is not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934.
- 7No new material financial events or significant business updates are disclosed in this specific 8-K filing.